A randomized, double-blind, multi-center, placebo-controlled dose ranging study to determine the safety, reactogenicity and immunogenicity of a single oral dose typhoid fever vaccine (Ty800) in healthy adult subjects

Trial Profile

A randomized, double-blind, multi-center, placebo-controlled dose ranging study to determine the safety, reactogenicity and immunogenicity of a single oral dose typhoid fever vaccine (Ty800) in healthy adult subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2008

At a glance

  • Drugs Typhoid vaccine Ty800 (Primary)
  • Indications Typhoid
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 02 Apr 2008 Results have been reported by AVANT Immunotherapeutics.
    • 17 Oct 2007 Status change from recruiting to in progress.
    • 08 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top